Stockscreener 앱 받기
17.87
1.25%
0.22
시장 영업 전:
17.86
-0.01
-0.06%
Odyssey Therapeutics Inc 주식(ODTX)의 최신 뉴스
FMR LLC's Strategic Acquisition of Odyssey Therapeutics Inc Shar - GuruFocus
IPO Tracker 2026: Kardigan stitches up $369M IPO plan - BioSpace
Anthony W. Opipari Net Worth (2026) - GuruFocus
Aranicki Ksenija Pavletic Net Worth (2026) - GuruFocus
Todd Collin M Net Worth (2026) - GuruFocus
Natalie Dales Net Worth (2026) - GuruFocus
Gary D Glick Net Worth (2026) - GuruFocus
FMR LLC discloses 4.58M-share stake in Odyssey Therapeutics (ODTX) - Stock Titan
Odyssey Therapeutics (ODTX) 10K Form and Latest SEC Filings 2026 - MarketBeat
ODTX Technical Analysis & ETF Price Forecast - Intellectia AI
Latest ODTX ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
ODTX Initiates Coverage by TD Cowen -- Rating Set to Buy - GuruFocus
ODTX Initiates Coverage by JP Morgan -- Price Target Set at $26 - GuruFocus
ODTX Initiated Coverage by Cantor Fitzgerald -- Rated Overweight - GuruFocus
ODTX Initiates Coverage by Wedbush -- Price Target Announced at $30 - GuruFocus
Odyssey Therapeutics (ODTX) Rated Outperform with $30 Target - GuruFocus
ODTX Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
This Oppenheimer Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
A Quick Look at Today's Ratings for Odyssey Therapeutics(ODTX.US), With a Forecast Between $16.96 to $40 - Moomoo
Wedbush Initiates Odyssey Therapeutics at Outperform With $30 Price Target - marketscreener.com
Oppenheimer initiates Odyssey Therapeutics stock with outperform rating By Investing.com - Investing.com South Africa
Oppenheimer initiates Odyssey Therapeutics stock with outperform rating - Investing.com
TD Cowen initiates Odyssey Therapeutics stock at Buy on drug pipeline - Investing.com
Cantor Fitzgerald Initiates Odyssey Therapeutics at Overweight - marketscreener.com
Oppenheimer Initiates Odyssey Therapeutics at Outperform With $40 Price Target - marketscreener.com
TD Cowen Initiates Odyssey Therapeutics at Buy - marketscreener.com
JPMorgan Initiates Odyssey Therapeutics at Overweight With $26 Price Target - marketscreener.com
JPMorgan initiates Odyssey Therapeutics stock rating at Overweight By Investing.com - Investing.com India
JPMorgan initiates Odyssey Therapeutics stock rating at Overweight - Investing.com
Odyssey Therapeutics (ODTX) Stock Analysis Report | Financials & Insights - Benzinga
Health stocks Odyssey, Mobia disappoint on first day of trading - MSN
ODTX|Odyssey Therapeutics Ord Shs (Proposed)|Price:17.500|Chg%:-0.24 - TradingKey
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
ODTX Technical Analysis | Trend, Signals & Chart Patterns | ODYSSEY THERAPEUTICS INC (NASDAQ:ODTX) - ChartMill
Odyssey Therapeutics hits $900M valuation in Nasdaq debut, stock climbs 13% before diving lower - MSN
ODTX SEC FilingsODYSSEY THERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Simeon George Discloses Investment at Odyssey Therapeutics with 8.0% Stake - TradingView
SR One funds disclose 8% Odyssey Therapeutics (ODTX) stake after IPO - Stock Titan
TPG funds take 7.8% Odyssey Therapeutics (ODTX) stake via $25M share purchase - Stock Titan
Odyssey Therapeutics (ODTX) Stock Forecast and Price Target 2026 - MarketBeat
Odyssey Therapeutics (ODTX) Stock Chart and Price History 2026 - MarketBeat
Dimension Management Discloses Investment at Odyssey Therapeutics with 7.1% Stake - TradingView
Jeito II S.L.P. Discloses Investment in Odyssey Therapeutics with 7.8% Stake - TradingView
What is the current Price Target and Forecast for Odyssey Therapeutics, Inc. (ODTX) - Zacks Investment Research
Immunology drug developer Odyssey seeks US IPO again - MSN
1.27%
1.43%
자본화:
|
볼륨(24시간):